Sunshine BiopharmaSBFM +1.87%34 PB Ratio is 0.05 as of Jun. 26, 2026, which is 81% below its 10-year median of 0.26. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Sunshine Biopharma ranks better than 99.67% on this metric.
Sunshine Biopharma Inc stock PB Ratio (=0.05) is close to 1-year low of 0.05.
The historical rank and industry rank for Sunshine Biopharma's PB Ratio or its related term are showing as below:
SBFM'
s PB Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.26 Max: 1.05
Current: 0.05
During the past 13 years, Sunshine Biopharma's highest PB Ratio was 1.05. The lowest was 0.01. And the median was 0.26.
SBFM's PB Ratio is ranked better than 99.67% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs SBFM: 0.05
During the past 12 months, Sunshine Biopharma's average Book Value Per Share Growth Rate was -47.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -87.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sunshine Biopharma was -87.10% per year. The lowest was -87.10% per year. And the median was -87.10% per year.
Back to Basics: PB Ratio
Sunshine Biopharma (NAS:SBFM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sunshine Biopharma PB Ratio Related Terms
Sunshine Biopharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sunshine Biopharma (SBFM) has a PB Ratio of 0.05 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunshine Biopharma and its competitors. This is 81% below median its historical median of 0.26. Over the past decade, Sunshine Biopharma's PB Ratio has ranged from 0.01 to 1.05. According to the industry distribution chart, Sunshine Biopharma ranks #3 out of 922 companies in the Drug Manufacturers industry, placing it in the top 0.3%.
Is Sunshine Biopharma's PB Ratio too high?
Sunshine Biopharma's current PB Ratio of 0.05 is 81% below median its 10-year median of 0.26. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.05. The Drug Manufacturers industry median PB Ratio is 1.83. Sunshine Biopharma's value of 0.05 is 97.3% below this industry median. Based on the distribution chart, Sunshine Biopharma ranks #3 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's PB Ratio compare to SNOA and CTTH?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #3 out of 922 companies for PB Ratio. This places Sunshine Biopharma in the top 0% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.83. Sunshine Biopharma's value of 0.05 is 97.3% below this benchmark. Historically, Sunshine Biopharma's own PB Ratio has ranged from 0.01 to 1.05 over the past decade. While the company's 10-year median is 0.26 vs. the industry median of 1.83, Sunshine Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Biopharma's current PB Ratio of 0.05 is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current PB Ratio is 0.05, which is 81% below median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.10, compared to a current price of $2.17 — trading 69.4% below its estimated fair value. The current PB Ratio is 0.05, which is 81% below median its 10-year median of 0.26 and 97.3% below the Drug Manufacturers industry median of 1.83. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current PB Ratio is 0.05 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Biopharma (SBFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued.
The current stock price of $2.17 is trading 69.4% below its estimated GF Value™ of $7.10.
GuruFocus considers Sunshine Biopharma to be Possible Value Trap.
Key valuation signals for SBFM:
PB Ratio: 0.05 (81% below median its 10-year median of 0.26)
GF Value™: $7.10 vs. price of $2.17 (69.4% below fair value)
Industry Position: 97.3% below the Drug Manufacturers median (#3 of 922)
No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFM has been successfully added to your 
